Compare iShares Global Tech ETF (IXN) vs Regeneron Pharmaceuticals Inc (REGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares Global Tech ETF vs Regeneron Pharmaceuticals Inc — how do they compare? iShares Global Tech ETF trades at $139.33, while Regeneron Pharmaceuticals Inc trades at $796.38 (market cap $83.19B). The key difference: Regeneron Pharmaceuticals Inc pays a 0.47% dividend while iShares Global Tech ETF pays none, and Regeneron Pharmaceuticals Inc is trading nearer its 52-week high, iShares Global Tech ETF nearer its low. Which is the better fit depends on your goals.
| IXN | REGN | |
|---|---|---|
Sector | Sector/Thematic | Health |
52-Week High | $149.74 | $812.27 |
52-Week Low | $94.42 | $555.51 |
Market Cap | — | $83.19B |
Enterprise Value | — | $77.90B |
Dividend Yield | — | 0.47% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IXN trades at $140.87, up 1.09% today, with a bullish technical signal from moving averages. The stock is near resistance at $141, with RSI indicating potential overbought conditions. Recent news highlights its global tech exposure, including AI developments from international firms.
Outlook is cautious due to high valuations and concentration risk in tech holdings. Opportunities exist from AI growth, but risks include stretched earnings expectations and market volatility. Analyst sentiment is mixed, favoring a hold rating for a better entry point.
Regeneron Pharmaceuticals (REGN) trades at $784.36, up 1.59% today, with a bullish technical signal from moving averages but overbought RSI readings. The company shows strong profitability with a net income margin of 27.86% and has beaten EPS estimates in recent quarters. However, multiple class-action lawsuits filed in August 2026 allege inadequate clinical-trial risk disclosures, creating investor uncertainty amid solid financial performance.
Outlook remains supported by earnings momentum and analyst buy ratings, but legal risks and high valuation multiples pose near-term headwinds. Investment opportunity hinges on legal resolution and sustained drug pipeline success, while risks include trial setbacks and regulatory scrutiny.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares Global Tech ETF
IXN provides exposure to global electronics, software, and hardware companies. It tracks the S&P Global 1200 Information Technology Index, covering tech leaders across both developed and emerging markets.
Read more on IXN →About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →
